AI Engines For more Details: Perplexity Kagi Labs You
Blood Pressure Reduction: Moxonidine works by stimulating alpha-2 adrenergic receptors in the brain, which leads to a reduction in sympathetic nerve activity and peripheral vascular resistance. This ultimately results in a decrease in blood pressure. Moxonidine is particularly effective in reducing systolic blood pressure.
Hypertension Management: Moxonidine is indicated for the management of essential hypertension, which refers to high blood pressure without an identifiable cause. It is often used as a first-line or adjunct therapy for individuals who do not achieve adequate blood pressure control with other antihypertensive medications.
Cardiovascular Protection: Lowering blood pressure with moxonidine can help reduce the risk of cardiovascular complications such as heart attack, stroke, and heart failure. By decreasing the workload on the heart and improving blood flow to vital organs, moxonidine may offer cardioprotective effects.
Renal Protection: Moxonidine has been shown to have protective effects on the kidneys by reducing intraglomerular pressure and proteinuria (protein in the urine). This may be beneficial in individuals with hypertension-related kidney damage or diabetic nephropathy.
Metabolic Effects: Moxonidine may have favorable effects on glucose metabolism and insulin sensitivity, making it a suitable choice for individuals with hypertension and metabolic syndrome or type 2 diabetes. It has been associated with lower fasting blood glucose levels and improved insulin sensitivity in some studies.
Adverse Effects: Common side effects of moxonidine include drowsiness, dry mouth, dizziness, headache, and gastrointestinal disturbances. These side effects are typically mild and transient. Moxonidine may also cause fluid retention, particularly in individuals with heart failure or impaired kidney function.
Central Nervous System Effects: As a centrally acting medication, moxonidine can affect the central nervous system and may cause sedation or drowsiness, especially when initiating therapy or increasing the dosage. It's important for individuals taking moxonidine to avoid activities that require mental alertness, such as driving, until they know how the medication affects them.
Drug Interactions: Moxonidine may interact with other medications, particularly those that affect blood pressure or heart rate. It's important to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting moxonidine therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.6 | 1.6 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2 | 1.2 | 0.67 |
| Allergies | 1.7 | 0.6 | 1.83 |
| Allergy to milk products | 0.6 | 1.3 | -1.17 |
| Alzheimer's disease | 2.1 | 1.9 | 0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.3 | 1.33 |
| Ankylosing spondylitis | 1.5 | 1 | 0.5 |
| Anorexia Nervosa | 0.7 | 1.2 | -0.71 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 1.9 | 1.1 | 0.73 |
| Atherosclerosis | 1 | 0.7 | 0.43 |
| Atrial fibrillation | 1.1 | 1.3 | -0.18 |
| Autism | 2.9 | 2.8 | 0.04 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2 | 2 | |
| Bipolar Disorder | 1.3 | 0.5 | 1.6 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 2.3 | 0.7 | 2.29 |
| Celiac Disease | 1.1 | 0.7 | 0.57 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 1.6 | 0.6 | 1.67 |
| Chronic Kidney Disease | 1.7 | 0.5 | 2.4 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.1 | 0.45 |
| Chronic Urticaria (Hives) | 1.2 | 0.1 | 11 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 0.8 | 1 |
| Cognitive Function | 1 | 0.8 | 0.25 |
| Colorectal Cancer | 4.2 | 1.2 | 2.5 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 1.6 | 0.9 | 0.78 |
| COVID-19 | 2.5 | 2 | 0.25 |
| Crohn's Disease | 3.7 | 1.6 | 1.31 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 0.8 | 0.13 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.4 | 1.1 | 0.27 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 4.1 | 2.9 | 0.41 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.6 | 0.4 | 3 |
| Endometriosis | 1.9 | 0.9 | 1.11 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.9 | 0.8 | 1.37 |
| erectile dysfunction | 1.2 | 1.2 | |
| Fibromyalgia | 1.3 | 0.3 | 3.33 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 1.3 | 0.62 |
| gallstone disease (gsd) | 1.8 | 0.8 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.3 | 1.67 |
| Generalized anxiety disorder | 2.2 | 0.6 | 2.67 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.3 | 0.1 | 2 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 1.2 | 0.3 | 3 |
| Heart Failure | 2.7 | 0.5 | 4.4 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.9 | 0.9 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 1 | 0.7 | 0.43 |
| hypertension (High Blood Pressure | 1.7 | 1.2 | 0.42 |
| Hypoxia | 1.6 | 1.6 | |
| IgA nephropathy (IgAN) | 1.3 | 0.9 | 0.44 |
| Inflammatory Bowel Disease | 3.4 | 1.9 | 0.79 |
| Insomnia | 0.6 | 1.1 | -0.83 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 2.9 | 1.6 | 0.81 |
| ischemic stroke | 1.3 | 1.4 | -0.08 |
| Liver Cirrhosis | 2.9 | 1.7 | 0.71 |
| Long COVID | 2.5 | 1.6 | 0.56 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 1.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.7 | 0.3 | 1.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.2 | 1.9 | 0.68 |
| Mood Disorders | 3.7 | 2.8 | 0.32 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 2.3 | 1.6 | 0.44 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 0.8 | 2.25 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.2 | 3.4 | -0.06 |
| obsessive-compulsive disorder | 2 | 1 | 1 |
| Osteoarthritis | 1.8 | 0.6 | 2 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 2.6 | 2.7 | -0.04 |
| Polycystic ovary syndrome | 3 | 1.1 | 1.73 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 1.9 | 0.8 | 1.37 |
| Psoriasis | 0.7 | 1.3 | -0.86 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.2 | 1.5 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.3 | 1.3 | 0 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 1.3 | 0.7 | 0.86 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 1.9 | 1.3 | 0.46 |
| Systemic Lupus Erythematosus | 2.4 | 0.8 | 2 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.3 | 1.1 | 0.18 |
| Type 2 Diabetes | 3.2 | 2.3 | 0.39 |
| Ulcerative colitis | 2.7 | 1.3 | 1.08 |
| Unhealthy Ageing | 1.8 | 1 | 0.8 |
| Vitiligo | 1.1 | 0.4 | 1.75 |
